Welcome to our dedicated page for Abpro Holdings SEC filings (Ticker: ABPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Abpro Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Abpro Holdings's regulatory disclosures and financial reporting.
Abpro Holdings, Inc. received notice from the Nasdaq Listing and Hearing Review Council that it reaffirmed a prior decision to delist the company’s securities from Nasdaq. The Council cited Abpro’s failure to meet the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline set in a November 10, 2025 panel decision.
Abpro expects Nasdaq to file a Form 25 to delist and deregister its securities under Section 12(b) of the Exchange Act. The company expects its common stock and public warrants to continue quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW,” but warns holders about potentially limited information availability, reduced transparency and liquidity, and greater trading volatility.
Abpro Holdings, Inc. reported a smaller net loss of $1,028 thousand for the quarter ended March 31, 2026, compared with $3,887 thousand a year earlier, as operating expenses fell sharply to $933 thousand from $2,958 thousand.
Cash rose to $5,398 thousand and total assets to $6,865 thousand, mainly from issuing 3,162,785 shares under its Standby Equity Purchase Agreement for gross proceeds of $7,264 thousand. Despite this, current liabilities of $9,117 thousand and a stockholders’ deficit of $2,252 thousand leave the company with negative equity.
Management states there is substantial doubt about Abpro’s ability to continue as a going concern within one year without additional financing. Its common stock was delisted from Nasdaq effective February 23, 2026 and now trades on the OTC Pink Limited market under “ABPO,” which may further hinder capital-raising efforts.
Abpro Holdings, Inc. filed an amended annual report to add Part III disclosures on directors, executive pay, ownership, related-party transactions, and auditor fees. The company’s common stock and warrants have been delisted from Nasdaq and trade on the OTC Pink tier as of February 23, 2026.
The board held 18 meetings in 2025, with all directors attending at least 75% of sessions, and three of four directors deemed independent. CEO Jin Wook (Miles) Suk earned a $250,000 salary and RSU awards valued at $261,792 in 2025 and is engaged through a consulting agreement providing a $300,000 annual fee and 500,000 RSUs, plus a change-of-control payout formula.
Former CEO Ian Chan and former Chief Medical Officer Robert Markelewicz received lower 2025 cash compensation before their terminations. As of March 30, 2026, 5,896,048 shares of common stock were outstanding, with sizeable stakes held by Abpro Bio International Inc., Atlantic Coastal Acquisition Management II LLC, and Ian Chan. The filing also outlines a clawback policy adopted in 2023 and notes 2025 audit and related fees totaling $483,250 for Wolf & Company and Marcum.
Abpro Holdings, Inc. is an early-stage biotechnology company developing next‑generation multispecific antibody drugs for cancer and eye diseases, built on its DiversImmune and TetraBi platforms. The company completed a reverse recapitalization with SPAC Atlantic Coastal Acquisition Corp. II in November 2024 and effected a 1‑for‑30 reverse stock split effective October 31, 2025.
Abpro’s lead oncology asset ABP‑102, partnered worldwide with Celltrion, received FDA clearance of its IND on January 6, 2026, enabling a Phase 1 trial in HER2‑positive solid tumors. Ophthalmology candidate ABP‑201 is licensed regionally to Abpro Bio, with additional T‑cell engager programs ABP‑110 and ABP‑150 in pre‑clinical development.
The business is highly capital constrained. Management discloses substantial doubt about its ability to continue as a going concern and relies on external financing. A $50 million Standby Equity Purchase Agreement with YA II PN, Ltd. funded approximately $1.0 million in 2025 and $6.7 million of net proceeds in early 2026, but became unavailable after Abpro’s common stock was delisted from Nasdaq on February 23, 2026 and moved to the OTC Pink Limited Market. As of June 30, 2025, non‑affiliate market value was about $9.3 million, and 5,896,048 common shares were outstanding as of March 30, 2026.